SOCM
SPRY icon

SR One Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

SR One Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.2M Hold
4,012,903
– – 3.52% 9
2025
Q4 		$46.8M Hold
4,012,903
– – 6.62% 6
2025
Q3 		$40.3M Hold
4,012,903
– – 5.83% 7
2025
Q2 		$70M Hold
4,012,903
– – 15.18% 2
2025
Q1 		$50.5M Hold
4,012,903
– – 12.97% 2
2024
Q4 		$42.3M Hold
4,012,903
– – 10.32% 2
2024
Q3 		$58.2M Hold
4,012,903
– – 11.67% 3
2024
Q2 		$34.1M Hold
4,012,903
– – 10.69% 3
2024
Q1 		$41M Hold
4,012,903
– – 11.26% 3
2023
Q4 		$22M Hold
4,012,903
– – 9.23% 2
2023
Q3 		$15.2M Hold
4,012,903
– – 7.77% 4
2023
Q2 		$26.9M Hold
4,012,903
– – 11.59% 4
2023
Q1 		$26.1M Buy
4,012,903
+1,003,226
+33% +$7.71M 9.73% 4
2022
Q4 		$25.7M Buy
+3,009,677
New +$19.5M 9.37% 3

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $921M AUM 60.37% 1-Year Est. Return

SR One Capital Management's SPRY Position: Q1 2026 in Review

SR One Capital Management held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 4,012,903 shares worth $32.2M. The position accounts for 3.52% of the portfolio, ranked #9.

SR One Capital Management first reported a position in SPRY in Q4 2022 and has held it in 14 quarters since. The position peaked at $70M in Q2 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • SR One Capital Management held 4,012,903 shares of ARS Pharmaceuticals worth $32.2M as of Q1 2026.
  • SR One Capital Management left its ARS Pharmaceuticals share count unchanged in Q1 2026.
  • ARS Pharmaceuticals made up 3.52% of SR One Capital Management's portfolio in Q1 2026, its #9 holding.
  • SR One Capital Management first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • SR One Capital Management's ARS Pharmaceuticals position peaked at $70M in Q2 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on SR One Capital Management's 13F filing for Q1 2026, filed 14 May 2026.